Tesamorelin and visceral fat: what the trials show

Key takeaways

• Tesamorelin (Egrifta WR) is FDA-approved (initial approval 2010) only for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, so any other use is off-label .
• The pivotal phase 3 trial cut visceral adipose tissue about 15 percent over 26 weeks at 2 mg subcutaneous daily (a 15.2 percent drop versus a 5.0 percent rise on placebo) .
• The visceral-fat reduction fades within months of stopping; continued dosing is what holds it .
• The label requires IGF-1 monitoring because the drug raises IGF-1, and it flags a roughly threefold higher risk of developing diabetes (hazard odds ratio 3.3) .
• Tesamorelin is on the WADA Prohibited List under S2 (peptide hormones and growth factors, GHRH analogs), banned in and out of competition .

Skip to:

• What tesamorelin is: a synthetic GHRH analog
• Mechanism: GHRH to growth hormone to IGF-1
• Phase 3: a 15 percent visceral-fat drop over 26 weeks
• What the trials actually measured
• Liver fat: a real signal, but only in HIV patients
• Off-label use: strong in HIV, thin everywhere else
• Monitoring: IGF-1 and blood sugar are the two to watch
• Label contraindications and warnings
• Doping status: banned by WADA at all times
• Product history: Egrifta, Egrifta SV, Egrifta WR
• What would actually move the off-label evidence map
• Editorial read

What tesamorelin is: a synthetic GHRH analog

Tesamorelin is a synthetic analog of growth-hormone-releasing factor (GRF, also called GHRH). It is built from the 44-amino-acid human GRF sequence with a hexenoyl group (a six-carbon chain with a double bond at position 3) attached at the N-terminus, which slows enzymatic breakdown . It works as a secretagogue, prompting the pituitary to release the body's own growth hormone; that is a different mechanism from recombinant HGH, which supplies growth hormone directly .

The FDA first approved tesamorelin in 2010 under the brand name Egrifta, with one labeled indication: reducing excess abdominal fat in HIV-infected adults with lipodystrophy . The current product is Egrifta WR, a more concentrated formulation the FDA approved in March 2025 that reconstitutes weekly rather than daily, per the manufacturer's announcement . The full product history is further down; the trial evidence below comes from the original 2 mg formulation.

Mechanism: GHRH to growth hormone to IGF-1

GHRH binds the GHRHR receptor on anterior pituitary somatotrophs, triggering a cyclic-AMP cascade that releases stored growth hormone into circulation. GH then acts at the liver and peripheral tissues, where it stimulates IGF-1 synthesis. IGF-1 mediates many of the downstream metabolic and trophic effects attributed to GH .

The N-terminal modification makes tesamorelin more resistant to the enzymes that clear native GHRH within minutes, so its longer effective half-life supports once-daily dosing while keeping the pituitary's pulsatile signaling. Because it drives the body's own pituitary output, the normal feedback brakes (somatostatin and IGF-1 negative feedback) stay in place, which is the main mechanistic difference from injecting growth hormone directly.

Phase 3: a 15 percent visceral-fat drop over 26 weeks

The pivotal phase 3 trial, reported by Falutz and colleagues in the New England Journal of Medicine in 2007, randomized 412 HIV patients with abdominal fat accumulation to tesamorelin 2 mg subcutaneously daily or placebo for 26 weeks. Visceral adipose tissue, measured by single-slice CT, fell 15.2 percent on tesamorelin and rose 5.0 percent on placebo .

A later pooled analysis of both phase 3 trials, with safety-extension data through 52 weeks, confirmed the visceral-fat reduction and showed that patients who kept dosing held their response (about a 17.5 percent VAT reduction maintained), while those switched to placebo drifted back toward baseline. That is the basis for treating tesamorelin as ongoing therapy: stop it and the fat comes back .

The same pooled analysis reported a drop in triglycerides and an improved total-cholesterol-to-HDL ratio alongside the visceral-fat change, plus a mean IGF-1 rise of about 108 ng/mL versus placebo .

What the trials actually measured

• Visceral fat fell about 15 percent (a 15.2 percent drop versus a 5.0 percent rise on placebo) over 26 weeks at 2 mg subcutaneous daily in HIV-associated lipodystrophy .
• The effect fades within months of stopping; continued dosing holds it .
• IGF-1 rose by design (about 108 ng/mL on average in the pooled analysis); some patients exceed the age-adjusted upper limit .
• Triglycerides fell and the total-cholesterol-to-HDL ratio improved in the pooled analysis .
• Common label adverse reactions: injection-site reactions (17 percent versus 6 percent on placebo), arthralgia (13 percent), peripheral edema, pain in extremity, and myalgia .
• Serious adverse events were uncommon in the trials, which ran 26 to 52 weeks and were not powered to detect differences in malignancy or cardiovascular events .

Liver fat: a real signal, but only in HIV patients

Two randomized trials looked at tesamorelin and liver fat, both in HIV patients. The first, Stanley and colleagues in JAMA in 2014, ran 6 months in 50 patients and reduced both visceral fat and liver fat (measured by magnetic resonance spectroscopy) versus placebo .

The larger follow-up, in Lancet HIV in 2019, ran 12 months and was built around fatty liver: hepatic fat fraction by proton magnetic resonance spectroscopy dropped about 4 percentage points more on tesamorelin than placebo, 35 percent of treated patients reached a hepatic fat fraction under 5 percent versus 4 percent on placebo, and fewer treated patients showed progression of liver fibrosis .

These data are genuinely encouraging, but they are specific to the HIV population. They do not make tesamorelin a proven fatty-liver therapy in non-HIV adults, where no trial has run at the scale a label needs. Off-label use for liver fat outside HIV is extrapolation, not confirmation.

Off-label use: strong in HIV, thin everywhere else

Outside HIV-associated lipodystrophy, tesamorelin comes up for general visceral fat, metabolic disease, and as a research probe for GH-axis activation. The trial base outside HIV is small. Anyone extrapolating should account for how different the starting point is: baseline GH-axis status, IGF-1, and insulin sensitivity in a healthy adult are not the HIV-lipodystrophy cohort that defined the label.

Visceral fat also responds to training, sleep, alcohol, and energy balance, so those levers sit upstream of any peptide and are worth pulling alongside it. Tesamorelin has label-grade evidence in one specific population and a much thinner literature everywhere else .

Monitoring: IGF-1 and blood sugar are the two to watch

Tesamorelin raises IGF-1 by design, so the label tells prescribers to monitor IGF-1 during therapy and to consider stopping if levels stay persistently elevated (for example above 3 standard deviations), especially when the efficacy response is weak .

Growth-hormone-axis activation can push blood sugar up. The label reports a higher rate of developing diabetes on tesamorelin than placebo (hazard odds ratio 3.3, 95 percent CI 1.4 to 9.6) and says to check glucose before and during treatment . If you run it off-label, IGF-1 and a fasting glucose or HbA1c are the two numbers not to skip; without them you are blind to the exact effects the label was built to catch.

Label contraindications and warnings

• Disrupted hypothalamic-pituitary axis: hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, or head trauma .
• Active malignancy. Raising GH and IGF-1 could in theory accelerate an existing cancer, so the label bars it outright .
• Pregnancy, because reducing visceral fat offers no benefit in pregnancy and could harm the fetus .
• Known hypersensitivity to tesamorelin or any of the excipients .

The label also carries a separate warning, not a contraindication, about critically ill patients: growth-hormone-axis activation was linked to higher mortality in acutely critically ill patients given high-dose GH, so treatment is weighed carefully in that setting .

Doping status: banned by WADA at all times

Tesamorelin is on the WADA Prohibited List in section S2 (peptide hormones, growth factors, related substances and mimetics), in the growth-hormone-releasing-factor subgroup with the other GHRH analogs. S2 substances are banned at all times, in and out of competition . USADA enforces that same list for US athletes, so the classification and the year-round ban apply to anyone in the testing pool .

Any athlete under WADA rules should treat tesamorelin as prohibited. A therapeutic-use exemption is possible in principle but rarely granted for off-label use; documented HIV-associated lipodystrophy would be the realistic TUE pathway.

Product history: Egrifta, Egrifta SV, Egrifta WR

The original Egrifta (2010) used a multi-vial reconstitution with sterile water for injection. Egrifta SV, approved in 2019, cut that down and is reconstituted daily. Egrifta WR, the more concentrated F8 formulation the FDA approved in March 2025, reconstitutes only weekly and delivers a labeled 1.28 mg once-daily subcutaneous dose; the manufacturer describes it as replacing Egrifta SV, though the two are not interchangeable because their doses and reconstitution steps differ . Because the labeled dose changed across formulations (the pivotal trials used the original 2 mg), dosing instructions do not carry over between labels, and working out the per-injection concentration from a vial strength and diluent volume is exactly what the peptide reconstitution calculator is for .

Compounded tesamorelin from sources outside FDA oversight is a different animal. The label and trial data here describe the approved product, not a compounded vial of unverified identity, concentration, or sterility. If you use a compounded source, those questions are yours to close: a third-party certificate of analysis and correct reconstitution math are the levers you actually control, and how to read a peptide COA walks through the first one.

What would actually move the off-label evidence map

• A randomized phase 2/3 trial of tesamorelin in non-HIV adults with NAFLD and central adiposity, with MRI-PDFF as the primary endpoint and IGF-1 / glycemic safety as secondary endpoints.
• A long-term cardiovascular outcomes trial, since the existing trials ran 26 to 52 weeks and were not powered for major cardiac events.
• Clear comparative data versus pure exercise or dietary visceral-fat interventions in matched populations.
• Long-term IGF-1 surveillance on chronic dosing to pin down the malignancy and glucose-tolerance signals.

Editorial read

Within its label, tesamorelin is one of the best-studied peptides in this catalog: a real phase 3 program, a clear visceral-fat effect, and known safety monitoring. Outside the label the evidence is thinner, and the monitoring (IGF-1, glucose) is the part most self-directed users skip. That is the gap to close if you run it: the drug does something measurable, but the numbers the label tracks are there for a reason.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 10 entries, primary canon (PubMed trials, the DailyMed label, PubChem, WADA and USADA) plus a manufacturer announcement acknowledged inline, last reviewed 2026-07-08.

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.